Hikma must add an Advair study

  
Generate a summary of this article
Listen to this article
Beta

Hikma has been told by the US Food and Drug Administration (FDA) to complete an additional clinical endpoint study to support its application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), following a dispute-resolution process with the US agency. Hikma had received an FDA complete response letter (CRL) in May 2017 indicating that its abbreviated new drug application (ANDA) was not ready for approval (Generics bulletin, 19 May 2017, page 1). And following disagreement with the FDA over the firm’s clinical endpoint study, Hikma took the matter to the agency’s disputeresolution process (Generics bulletin, 17 November 2017, page 13). “Upholding its original determination”, the FDA has insisted on an additional clinical endpoint study.

Hikma has been told by the US Food and Drug Administration (FDA) to complete an additional clinical endpoint study to support its application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), following a dispute-resolution process with the US agency. Hikma had received an FDA complete response letter (CRL) in May 2017 indicating that its abbreviated new drug application (ANDA) was not ready for approval (Generics bulletin, 19 May 2017, page 1). And following disagreement with the FDA over the firm’s clinical endpoint study, Hikma took the matter to the agency’s disputeresolution process (Generics bulletin, 17 November 2017, page 13). “Upholding its original determination”, the FDA has insisted on an additional clinical endpoint study.

“In anticipation of this as one of the potential outcomes, Hikma has already finalised the planning of a new clinical...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.